Member Info for Iano

Https://www.nampa.org/text/22945440.

This wasn't the page but just found this one.

I'm just trying to find the info,

will post link when I find it again

Following the auction, Giquello stated that while the bag did not find a buyer in the room, the event successfully generated significant interest from private collectors and brands. He indicated that negotiations are already underway to sell the bag privately in the coming days, suggesting the high-profile auction served its purpose as a marketing catalyst for the biotechnology behind the material.

No one knows if it sold yet?

Global Blockchain & Crypto Symposium: A legal and regulatory-focused symposium; the 2026 edition is set for 24 June 2026, following the successful 2025 event at the Banking Hall.

Citywealth Crypto Club: Greengage is attending upcoming evening sessions (e.g., 18:30 start) to engage in discussions on digital assets and wealth management.

Industry Advocacy: Greengage actively participates in CryptoUK events, including the Crypto & Digital Assets APPG Roundtable in Parliament, and supports the Stand With Crypto UK movement to shape UK regulatory policy.

See someone splashed out £10 at 0.60

CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma.

https://www.cellcentric.com/press-release/cellcentric-announces-oversubscribed-220-million-series-d-financing-to-advance-pivotal-trials-of-inobrodib-in-multiple-myeloma/

With the biopharma industry in the region valued at $22 billion, there are a number young biotechs looking to make it big in the sector in hopes that their first-in-class drugs make it to the market. Here are five South Korean biotech startups in the clinic that have captured investors in recent years and are broadening research and development (R&D) in various therapeutic areas.

https://www.labiotech.eu/best-biotech/biotech-companies-south-korea/

Welcome.

Https://www.asx.com.au/markets/company/GGP

See below for a summary of why PYC is so under valued:

1. Dealmakers in pharmaceuticals and life sciences and in healthcare services are eager to get deals done.

2. Competition for truly innovative assets remains intense.

3. Large pharmaceutical companies will continue to pursue biotech targets and products that can offset revenue declines from lost exclusivity in the coming years.

4. Companies seeking opportunities to digitalise through implementation of analytics technology, digital direct-to-consumer therapeutics offerings, smart health devices and other software innovations will continue to acquire or partner with data and analytics and other technology companies that can deliver these digital solutions.

For example:

5. Merck: Acquired Harpoon Therapeutics for an estimated $680 million

6. Novartis: Acquired Calypso Biotech for $250 million

7. Aditxt: Acquired Evofem Biosciences for $100 million

8. There were 420 M&A deals in our sector globally in Q3 2024, worth a total value of $32.4bn. Source: GlobalData’s Deals Database.

9. The $3.2bn acquisition of Morphic Holdings by Eli Lilly and Co was the industry’s largest disclosed deal in Q3 2024.

10. Interestingly for PYC investors AI / State of the art virtual technology accounted for 11 pharmaceutical deals announced in Q3 2024, worth a total value of $1.7bn. The $1.1bn acquisition of Integrated Oncology Network by Cardinal Health was the industry’s largest disclosed deal.

hxxps://www.pwc.com/gx/en/services/deals/trends/health-industries.html

Happy New Year, 👍

Https://x.com/Physiomics/status/1875135022044201324?t=xunrUWZTyuZ5Q9mnOqy0bA&s=19

''Mark’s expertise enhances our ability to deliver critical insights, while his creative approach to solving complex drug development challenges – including the use of real-world data (RWD) – brings new opportunities for advancing innovation''

The FDA issued a release on 1st October, 2024 relating to the use of RWD. Here is an extract :-

FDA has a long history of using what we currently call real-world data (RWD) and real-world evidence (RWE) to monitor and evaluate the post market safety of approved drugs. RWE has also been used historically to support effectiveness, but on a more limited basis. Advances in the availability and analysis of RWD have increased the potential for generating robust RWE to support FDA regulatory decisions.

FDA is committed to realizing the full potential of fit-for-purpose RWD to generate RWE that will advance the development of therapeutic products and strengthen regulatory oversight of medical products across their lifecycle.

Real-world data are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. Examples of RWD include data derived from electronic health records, medical claims data, data from product or disease registries, and data gathered from other sources (such as digital health technologies) that can inform on health status. Real-world evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD.

Https://x.com/Geez79177095 chart and first target price the MA50 at 1.025

Https://pharmaphorum.com/digital/seeking-effective-safe-treatment-all-precision-dosing worth reading, 👍

Physiomics marks record year with expanding consultancy and personalized medicine initiatives

https://www.proactiveinvestors.co.uk/companies/news/1060124/physiomics-marks-record-year-with-expanding-consultancy-and-personalized-medicine-initiatives-1060124.html?viewSource=TwitterUK

Docetaxel is predominantly used for prostate cancer and the tool is being developed for that however this maybe able to support other types of cancer moving forward…..route to market via Dosemerx

The precision application will save time in favour of the patient and hopefully help overall survival.

Naturally saving time and dosing will save significant amounts of money…

Docetaxel market size was valued at USD 114.78 billion in 2023 and it is estimated to reach USD 252.46 billion in 2032.

Huge numbers for the potential DoseMeRx/PYC venture

This time last year PYC did 300% once the placing was churned.

The recent volume 2 weeks ago of 150mln was 3x the placing

So Looks set to have another huge August September rise.

Learn about our collaboration with @Bicycle_tx! 🚀 Together, we've developed a PK/PD modelling framework to explore dosing & scheduling for BT7480, a novel, first-in-class Bicycle tumour-targeted immune cell agonist.